One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients-Reference-Cited by-同舟云学术

One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients

Published:2018-11-28 Issue:1 Volume:139 Page:26-36
ISSN:0001-690X
Container-title:Acta Psychiatrica Scandinavica
language:en
Short-container-title:Acta Psychiatr Scand

Author:

Svensson C. K.¹^ORCID,Larsen J. R.¹²,Vedtofte L.³,Jakobsen M. S. L.¹,Jespersen H. R.¹,Jakobsen M. I.¹^ORCID,Koyuncu K.¹,Schjerning O.⁴,Nielsen J.⁵,Ekstrøm C. T.⁶,Correll C. U.⁷⁸⁹^ORCID,Vilsbøll T.³¹⁰,Fink-Jensen A.¹¹⁰

Affiliation:

1. Psychiatric Centre Copenhagen; Rigshospitalet; Mental Health Services; Capital Region of Denmark, Copenhagen Denmark

2. Novo Nordisk A/S; Bagsvaerd Denmark

3. Clinical Metabolic Physiology; Steno Diabetes Center Copenhagen; Gentofte Hospital; University of Copenhagen; Hellerup Denmark

4. Department of Psychiatry; Aalborg University; Aalborg Denmark

5. Psychiatric Centre Glostrup; University of Copenhagen; Copenhagen Denmark

6. Department of Public Health; Section of Biostatistics; University of Copenhagen; Copenhagen Denmark

7. Department of Psychiatry; The Zucker Hillside Hospital; Northwell Health; Glen Oaks NY USA

8. Department of Psychiatry and Molecular Medicine; Hofstra Northwell School of Medicine; Hempstead NY USA

9. Department of Child and Adolescent Psychiatry; Charité Universitätsmedizin; Berlin Germany

10. Department of Clinical Medicine; Faculty of Health and Medical Sciences; University of Copenhagen; Copenhagen Denmark

Funder

Novo Nordisk

Lundbeckfonden

Publisher

Wiley

Subject

Psychiatry and Mental health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/acps.12982/fullpdf

Reference59 articles.

1. Excess early mortality in schizophrenia;Laursen;Annu Rev Clin Psychol,2014

2. Antipsychotic drugs and obesity;Correll;Trends Mol Med,2011

3. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses;Henderson;Lancet Psychiatr,2015

4. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs;Hert;Nat Rev Endocrinol,2012

5. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis;Vancampfort;World Psychiatry,2015

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia;CNS Drugs;2023-12-14

2. Clinical assessment of liraglutide use in prediabetic and obese schizophrenic patients: A systematic literature review and meta-analysis;2023-08-02

3. A look at the GLP‐1 agonists;The Brown University Psychopharmacology Update;2023-07-28

4. Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia;CNS Drugs;2023-07

5. Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis;Diabetes/Metabolism Research and Reviews;2023-06-25